BofA Securities Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $61
BofA Securities analyst Tazeen Ahmad maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and adjusts the target price from $66 to $61.According to TipRanks data, the analyst has a
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Apellis Pharmaceuticals, Inc. (APLS): Among the Best Mid-Cap Healthcare Stocks To Buy Now
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Profit Outlook